Nuvanto Bioscience Profile
Key Indicators
- Authorised Capital ₹ 1.36 Cr
as on 26-07-2024
- Paid Up Capital ₹ 1.14 Cr
as on 26-07-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -29.90%
(FY 2023)
- Profit -547.27%
(FY 2023)
- Ebitda -228.89%
(FY 2023)
- Net Worth -11.87%
(FY 2023)
- Total Assets 6.99%
(FY 2023)
About Nuvanto Bioscience
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.36 Cr and a paid-up capital of Rs 1.14 Cr, as per Ministry of Corporate Affairs (MCA) records.
Roy, Sarala Sadasivan, and Sajish Sadasivan serve as directors at the Company.
- CIN/LLPIN
U15135KA2018PTC116518
- Company No.
116518
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nuvanto Bioscience Private Limited offer?
Nuvanto Bioscience Private Limited offers a wide range of products and services, including Flavours & Aromatics, Sweetener, Artificial Sweetener, Chemical Reagents & Catalysts, Organic Salt.
Who are the key members and board of directors at Nuvanto Bioscience?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Roy  | Additional Director | 17-May-2022 | Current |
| Sarala Sadasivan | Director | 20-Sep-2018 | Current |
| Sajish Sadasivan | Additional Director | 03-Apr-2024 | Current |
Financial Performance of Nuvanto Bioscience.
Nuvanto Bioscience Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 29.9% decrease. The company also saw a substantial fall in profitability, with a 547.27% decrease in profit. The company's net worth observed a substantial decline by a decrease of 11.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nuvanto Bioscience?
In 2023, Nuvanto Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nuvanto Bioscience?
Unlock and access historical data on people associated with Nuvanto Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nuvanto Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nuvanto Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
